News and Media

Clinuvel attracts worldwide media attention for its development program with afamelanotide. A selection of recent press can be found here.

Clinuvel releases a regular newsletter to shareholders, which is also released to the ASX. You can subscribe to receive our newsletter, and other ASX announcements, here.